Professionals 228 Users Online

Flu Vaccines Market

Growth in Awareness Campaigns Regarding Influenzas are Driving the Flu Vaccines Market

Flu Vaccines Market by Product (Trivalent Flu Vaccine and Quadrivalent Flu Vaccine)

Flu Vaccines Market Outlook (2023 to 2033)

The global revenue from the Flu Vaccines Market was approximately US$ 5.06 Billion in 2022, with the global market expected to grow at a CAGR of 6.7% to reach a valuation of approximately US$ 10.19 Billion by the end of 2033.

Market Size (2023)

US$ 5.40 Billion

Projected Market Value (2033)

US$ 10.19 Billion

Global Market Growth Rate (2023 to 2033)

6.7% CAGR

Market Share of Top 5 Countries

78.8%

As assessed by Persistence Market Research quadrivalent flu vaccines held around 83.8% of the global flu vaccines market, in 2022. The global flu vaccines market holds nearly 3.6% revenue share of the global vaccine market valued at US$ 141.0 Billion in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Flu Vaccines Market from 2014 to 2022 Vs Market Outlook for 2023 to 2033

The Global Flu Vaccines Market recorded a historic CAGR of 6.3% in the last 8 years from 2014 to 2022.

The global flu vaccines market is likely to show high growth over the coming years at a CAGR of 6.7% and reach a global market size of 10.19 Billion by 2033.

Flu Vaccines are biological agents that, when administered, cause the body to produce antibodies that protect against contact with the influenza virus. Within two weeks of the vaccine, the body begins to produce antibodies. Flu vaccines are becoming more and more popular they stop and lessen the spread of the influenza virus. Due to the expansion of the new target demographic across developing and underdeveloped countries, the market is expanding significantly.

The awareness efforts for the prevention of infectious diseases affecting on the market expansion. By increasing vaccines’ level of protection and delivering innovations to the market, many biotech businesses are constantly upgrading the available vaccinations.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What Factors will Drive the Market to Grow over Forecast Duration?

“Increasing flu vaccination rate and cost-effectiveness of vaccines accelerating the flu vaccines market growth

Flu vaccination rates are rapidly increasing across many regions, which can be attributed to ongoing efforts by local governments to increase public awareness of the illness as well as programs run by organizations like the World Health Organization (WHO), Global Alliance for Vaccines and Immunization (GAVI), The Pan American Health Organization (PAHO), etc.

Also, according to the government of Canada, Canada set a target of vaccinating 80% of people who were more likely to develop flu complications by 2021. This includes people over 65 and adults with chronic medical issues who are 18 to 64 years old. Only 38% of Canadian adults 18 to 64 years old with chronic medical conditions obtained the flu vaccination during the 2021 to 2022 flu season. Vaccination rates among seniors (71%) are closer to the desired level of 80%.

The probability of a pandemic, the availability of insurance coverage during a potential pandemic, sufficient supply and demand, and research and development are some of the key elements of flu vaccine storage.

In developing countries like India, China, Brazil, and others, local manufacturers frequently produce a large number of less expensive vaccines, increasing access to flu vaccines.

“Rising awareness about flu vaccination to raise opportunities in the market.”

Throughout the forecast period, there should be significant prospects for income generation due to rising global awareness of the importance of getting vaccinated against the flu. Each year, the flu vaccine saves thousands of lives by preventing hospitalizations. For instance, the CDC estimates that flu vaccination during 2019 to 2020 avoided 105,000 hospitalizations due to the flu.

Parallel to this, some producers of flu vaccines are attempting to expand their regional product footprints, either independently or through mergers and acquisitions. As a result, the manufacturers are given profitable prospects by such elements.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Is there any Impact on the Growth of the Flu Vaccines Market?

The gap between supply and demand in flu vaccines may hamper the market.

The severity of the seasonal flu has a major impact on the demand for flu vaccines. Further, numerous awareness efforts are being run all over the world, which has aided in raising public awareness and boosting vaccination rates. Demand and supply gaps are caused by the seasonal flu's unpredictable nature and the varying estimates made by the WHO, which are occasionally overestimated.

A conservative approach has also been adopted by several vaccine manufacturing companies due to the flu's unpredictable incidence, which has resulted in a lesser supply of vaccines even during pandemics or subsequent outbreaks. This is another issue impeding the market's expansion.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the United States Market Booming?

“Increasing supply of flu vaccines by manufacturers in the country is driving the market.”

The United States accounted for around 60.1% market share in the global market in 2022.

The Centers for Disease Control and Prevention received an estimate from vaccine manufacturers that the country will get between 173.5 million and 183.5 million doses of the influenza vaccine for the season 2022-2033. GSK will continue to support yearly immunization across the US while continuing to supply more than 50 million doses of its influenza vaccine to the US market, it will continue to support yearly immunization across the US.

Will Japan be a Lucrative Market for Flu Vaccines?

“Need to control bird flu infections is driving the market in the country”

The Japanese market held around 6.2% market share in the global flu vaccines market in 2022.

As a result of the unprecedented rise in avian influenza cases across the country, 9.98 million birds at chicken farms in Japan have been killed in 2022.

According to the Ministry of Agriculture, Forestry, and Fisheries, a poultry farm in the town of Shirosato in the Ibaraki prefecture earlier verified a bird flu epidemic and has begun culling roughly 930,000 hens at the facility.

Hence, corresponding incidences in the country spreading awareness about the flu which is aiding the market growth.

What is Market Outlook for Germany?

Higher German flu vaccination program to uplift the market.

Germany held a market share of about 4.4% in the global market in 2022.

In Germany, millions of people contract the flu each winter. Children are most at risk for contracting the sickness and spreading it to others, with older persons and those with chronic illnesses being at higher risk for complications from influenza. German vaccination programs are currently being expanded to include healthy children as well as high-risk children, to increase vaccination coverage rates, provide direct protection against infection, and slow the spread of disease to the general population. At the same time, elderly and high-risk populations-including pregnant women, children, and other age groups with chronic diseases-are being targeted by the country's current vaccination policies.

How is China Emerging as a Prominent Market for Flu Vaccines Market?

“Development of china’s vaccine manufacturing industry is aiding the market growth.”

China held a market share of about 4.4% of the global market in 2022.

The development of the regulatory scenario in China has considerably accelerated the growth of the vaccination sector in that nation. According to the study on the development of china's vaccine industry in the past decade. The estimated annual dose of flu vaccines in China was 769.66 million injections, and the overall production was balanced. In total, fourteen additional vaccinations were added, six of which were from China.

Category-wise Insights

Which Product is Driving Demand within the Global Market?

“Accessible of vaccines and increased approvals of the quadrivalent vaccines.”

The Quadrivalent Flu Vaccine held around 83.8% share of the total market in 2022, because of its affordability, effectiveness in combating viral infections, and accessibility in clinics and hospitals. Four distinct influenza viruses, involving two influenzas A and two influenza B viruses, are covered by the quadrivalent influenza vaccination. The market's expansion is also anticipated to be fuelled by the drug approvals for the quadrivalent kind of vaccine.

Which Dosage Form is Adopted within the Global Market?

“Due to the advantages intramuscular injections have over other kinds of approaches"

Intramuscular injection held around 93.6% share of the total market in 2022.

To administer drugs deep inside the muscle, intramuscular injections are employed. Due to the abundant blood flow to muscle tissue, medicines injected into the muscle are quickly absorbed into the bloodstream. The doctor may also administer an intramuscular shot. If they can't find the right vein, the medication will irritate the veins and make pills useless due to the digestive system.

Which Distribution Channel is Widely Adopted?

“To increase product reach and the high volume sales to increase the adoption rate for surgical and respiratory masks.”

Institutional sales held around 68.3% share of the total market in 2022.

The Flu Vaccine Program is made to specifically address the requirements of healthcare facilities like hospitals, retail pharmacies, doctor's offices, and community health centers. The institutional sales serve as a one-stop shop for a variety of flu vaccination brands, pre-book discounts, prompt and dependable delivery, and ongoing support. Consequently, institutional sales are in the lead.

Competition Landscape

The business’s main priorities are to increase production volume, improve its line of vaccines, introduce advanced features, and introduce new products. For accelerated and improved manufacturing, several market players are operating various segments to expand their portfolios.

  • Sanofi reports encouraging Phase 1/2 trial midpoint findings for its initial mRNA-based vaccine candidate. Comparable tolerance to another non-modified mRNA COVID-19 vaccines and high seroconversion all over the three dosages tested. Accelerating the conversion of the acquired technology to modified mRNA with a 2022 clinic launch target for a modified quadrivalent flu vaccine
  • The first qHPV vaccine produced in India, called "CERVAVA," has been released by the Serum Institute of India. The Bill and Melinda Gates Foundation, Serum Institute of India (SII), Department of Biotechnology (DBT), and Biotechnology Industry Research Assistance Council (BIRAC) collaborated to develop India's first locally produced quadrivalent human papillomavirus vaccine (qHPV), known as "CERVAVAC."

Flu Vaccines Industry Report Scope

Attribute

Details

Forecast Period

2023 to 2033

Historical Data Available for

2014 to 2022

Market Analysis

  • USD Billion for Value
  • Units for Volume

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • BENELUX
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Türkiye
  • GCC Countries
  • North Africa
  • South Africa

Key Market Segments Covered

  • Product
  • Dosage Form
  • Distribution Channel
  • Region

Key Companies Covered

  • Sanofi Pasteur Inc.
  • AstraZeneca
  • Csl Ltd.
  • Abbott
  • GlaxoSmithKline Plc.
  • Serum Institute Of India Pvt.Ltd

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Flu Vaccines Industry Research

Product:

  • Trivalent Flu Vaccine
  • Quadrivalent Flu Vaccine

Dosage Form:

  • Intramuscular Injection
  • Nasal Spray
  • Intradermal Shot

Distribution Channel:

  • Institutional Sales
    • Hospitals
    • Community Clinics
    • Public Health Agencies
    • Workplace Purchasing
  • Retail Sales
    • Retail Pharmacies
    • Mail Order Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

- Companies Covered in This Report -

  • Sanofi Pasteur Inc.
  • Astrazeneca
  • Csl Ltd.
  • Abbbott
  • Glaxosmithkline Plc.
  • Serum Institute of India Pvt.Ltd

- Frequently Asked Questions -

The global market is currently valued at around US$ 5.06 Billion in 2022.

Sales of the market are set to witness growth at a CAGR of 6.70% and be valued at around US$ 10.19 Billion by 2033.

Demand for the global market increased at a 6.30% CAGR from 2014 to 2022.

The U.S., Japan, Germany, China, and, the U.K. account for most demand within the market, currently holding around 78.8% market share.

The U.S. accounts for around 60.1% share of the global market in 2022.

North America accounts for around 62.4% market share of the global market in 2022.

The China market held a share of about 4.4% in the global flu vaccines market in 2022.

The German flu vaccines market held a share of 4.4% in the global market in 2022.

The Japan flu vaccines market held a share of 6.2% in the global market in 2022.

The flu vaccines market in the U.K. held around 3.7% market share in 2022.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate